In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Anacor gets $50mm including investments from GSK, Schering

Executive Summary

Just two weeks after withdrawing its IPO, Anacor Pharmaceuticals (developing compounds for fungal, bacterial, and inflammatory diseases) raised $50mm through the sale of preferred shares to returning shareholders Rho Capital Partners, Venrock Associates, Care Capital, and Aberdare Ventures. Also contributing were GlaxoSmithKline and Schering to fulfill obligations as part of separate 2007 licensing agreements with Anacor. The company will use the proceeds for ongoing development of its boron chemistry-based candidates.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies